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Discussion 
 Early insulin intervention improves β-cell 
function as well as insulin sensitivity 
 When MDI and CSII are compared, CSII 
produces better glycemic control in T2DM 
patients 
 Patch pump insulin delivery systems such as 
the V-Go and OmniPod have been proven to 
be functionally sound and effective for 
glycemic control in T2DM 
 Patch pumps have also received favorable 
reviews from patients which may impact 
patient compliance and therefore long-term 
glycemic control 
 
DM is a leading cause of death in Americans 
A HbA1c above 6.5% is diagnostic for DM 
because it is at this level the patient is at risk 
for retinopathy and other microvascular 
disease 
 The purpose of this study is to determine 
alternative methods of maintaining tighter 
control on HbA1c to lessen the effects of type II 
diabetes.  
 
 
 
 Set glycemic goals on an individualized basis, 
keeping HbA1c below 7.0% for most patients 
ADA recommends metformin as the first-line 
drug of choice to a maximum of one gram 
three times per day. If glycemic goals are not 
met on monotherapy with metformin, current 
guidelines suggest the addition of a second or 
third oral antidiabetic  
 If glycemic goals are still not met, an injectable 
antidiabetic medication such as glucagon-like 
peptide-1 (GLP-1) receptor agonist or insulin 
are indicated 
 Insulin has traditionally been a last line 
therapy for T2DM, however evidence suggests 
earlier intervention could provide better 
patient outcomes 
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Introduction  
 Type II diabetes accounts for approximately 
90-95% of all diabetes cases 
DM carries a high rate of comorbidities such as 
kidney disease, blindness, and heart disease 
that lead to diminished quality of life, life 
expectancy, and increased cost of health care. 
 
 
With Type II Diabetes on the rise, studies are 
needed to show which methods of insulin 
delivery are most desirable for this patient 
population.  
 
Introduction  
 Is insulin the most effective/appropriate 
therapy for treatment of type II diabetics who 
fail oral antidiabetic drugs?  
 In Type II diabetic patients, are insulin patch 
pumps more effective than traditional insulin 
delivery systems for the control of HbA1C?  
 
Pathophysiology 
 Early, intense insulin therapy in T2DM safely 
improved β-cell function in a multiethnic 
sample of patients 
Achieving good glycemic control sooner than 
later significantly reduces the risk of diabetic 
complications 
Patients achieved better HbA1c control, used 
less insulin and reported better quality of life 
on insulin pump over multi-dose regimen 
V-Go patch pump showed decreased fasting 
plasma glucose and HbA1c and rebound after 
discontinuance 
 
 
 
 
 
 
 
HbA1c  greatly decreased in the first 3 months 
of OmniPod use 
Patients reported more satisfaction with patch 
pump 
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